Trial record 1 of 1 for:    209as209
Previous Study | Return to List | Next Study

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01706523
Recruitment Status : Terminated
First Posted : October 15, 2012
Last Update Posted : July 31, 2013
Information provided by (Responsible Party):
Seaside Therapeutics, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : July 2013
  Estimated Study Completion Date : July 2013